Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Neutropenia 1Chemotherapy-Induced Febrile Neutropenia 1Breast Neoplasms 1

Interventions

Filgrastim 6pegylated granulocyte colony-stimulating factor 4pegfilgrastim 4Vancomycin 3Etoposide 3Cytarabine 3Cefepime 3Amikacin 3Teicoplanin 2Methotrexate 2Meropenem 2Granulocyte Colony-Stimulating Factor 2Daunorubicin 2Cyclosporine 2Ciprofloxacin 2Ceftazidime 2ziprasidone 1niraparib 1lintuzumab 1leridistim 1fludarabine phosphate 1angiotensin I (1-7) 1Zolpidem 1Warfarin 1Vitamin B 12 1Vincristine 1Vecuronium Bromide 1Transplantation 1Tranexamic Acid 1Tobramycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neutropenia × MYL-1401H × Classical hematology × Clear all
NCT02467868 2022-02-14

Efficacy and Safety Study With MYL-1401H and Neulasta

Viatris Inc.

Phase 3 Completed
193 enrolled
BreastClassical hematology

Breast Neoplasms, Neutropenia, Chemotherapy-Induced Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡